Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

Rhea-AI Summary

Amicus Therapeutics (FOLD) has announced its participation in two major investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference in New York on June 4 at 11:40 a.m. ET and at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 10 at 2:00 p.m. ET. Both presentations will be accessible via live audio webcast through the investor relations section of Amicus' corporate website. Amicus Therapeutics is a global biotechnology company dedicated to developing and delivering innovative medicines for rare diseases, with a strong focus on patient care and advancing their pipeline of first- or best-in-class treatments.

News Market Reaction

-2.25%

1 alert

-2.25% News Effect

On the day this news was published, FOLD declined 2.25%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June.

• Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at 11:40 a.m. ET
• Goldman Sachs 46^th Annual Global Healthcare Conference 2025 in Miami, FL, on Tuesday, June 10, 2025, at 2:00 p.m. ET

A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G